GeoVax Labs to Announce Q2 2025 Financial Results and Provide Corporate Update

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has announced it will release its second quarter 2025 financial results on July 28, 2025, after the U.S. markets close. This will be followed by a conference call and webcast at 4:30 p.m. ET to discuss the financial outcomes and provide an update on corporate developments. The live conference call can be accessed by registering here, with the webcast available in the Investor Relations section of the GeoVax website. For those preferring telephone participation, dial-in information will be provided upon registration. A replay of the webcast will be made available on the company's website two hours after the call concludes and will remain accessible for 90 days.

GeoVax's current pipeline features GEO-CM04S1, a next-generation COVID-19 vaccine currently in Phase 2 trials, and Gedeptin®, an innovative oncolytic therapy aimed at treating solid tumors. Additionally, the company is preparing a vaccine targeting Mpox and smallpox for Phase 3 trials. These developments reflect GeoVax's dedication to leveraging its innovative approach and extensive intellectual property portfolio to meet critical needs in vaccine and therapy development, addressing some of the most pressing challenges in infectious diseases and oncology.